AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...
Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback